SaleJul 28, 2026, 06:08 AM
Denali Sells PRV for $195M After AVLAYAH Approval
AI Summary
Denali Therapeutics Inc. announced the completion of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) to a large pharmaceutical company. The company received gross proceeds of $195.0 million from this transaction. Denali had obtained the PRV following the U.S. FDA approval of AVLAYAHTM (tividenofusp alfa) for Hunter syndrome in March 2026.
Key Highlights
- Denali Therapeutics completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV).
- The company received gross proceeds of $195.0 million from the sale.
- The PRV was sold to a large pharmaceutical company.
- Denali received the PRV after AVLAYAHTM (tividenofusp alfa) was approved by the U.S. FDA in March 2026.
- The sale was completed on July 27, 2026, under an agreement dated June 12, 2026.
Price Impact
More from DNLI